NHNaim Haddad

Naim Haddad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naim Haddad has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New-Onset Refractory Status Epilepticus (NORSE)

    by Gayane Melykian, Faisal Ibrahim, Gonzalo Alarcon, Naim Haddad, Hassan Al Hail, Dirk Deleu, Lubna El Sheikh, Yazan Nofal, Boulenouar Mesraoua

    New-onset refractory status epilepticus (NORSE) is defined as refractory status epilepticus without an obvious cause after initial investigations; “Initial” means 24 to 48 hours, to exclude stroke, other structural brain damage, drug overdoses and herpetic encephalitis. In the state of refractory status epilepticus (ES), patient suffers from repeated epileptic seizures without recovery of consciousness in between (Status epilepticus); these seizures do not respond to standard antiseizure medications (this refers to “refractory”). Recent studies suggest that these crises could be caused by an excess of pro-inflammatory molecules following a viral infection of the brain; however no evidence confirming this hypothesis has been demonstrated to date. Patients with NORSE are in the vast majority treated in intensive care units for several weeks or even months; despite the use of aggressive treatments such as therapeutic coma, and also immunotherapy, patients with NORSE face a high rate of complications and mortality; however a significant proportion of them eventually recover. NORSE survivors frequently suffer from epilepsy and cognitive impairment, a small minority eventually return to a normal lifestyle.


  • Open Access

    Etiology of Status Epilepticus

    by Marjan Asadollahi, Rola Hosni Al Khodair, Hassan Al Hail, Tahera Thekkumputath, Dirk Deleu, Naim Haddad

    The etiology of status epilepticus (SE), plays a major role in determining its prognosis and is subdivided into two main categories of “known” or “symptomatic” and “unknown” or “cryptogenic”. Symptomatic means a SE caused by known affections of the central nervous system (structural, inflammatory, infectious, toxic-metabolic, or genetic). These can be acute, remote and progressive. In addition, specific electroclinical syndromes can also be the cause of SE. Metabolic, toxic or other factors are largely responsible for SE in idiopathic or genetic epileptic syndromes. However, despite an extensive search, the etiology of SE remains largely unknown; in these cases, investigations looking for a neurological injury or a factor that triggered SE is negative. In this chapter, we will highlight the importance of determining the etiology of SE, as it can play a critical role in decisions about the treatment of SE and the patient’s management.


  • Open Access

    Advances in the Treatment of Status Epilepticus

    by Naim Haddad, Gayane Melikyan, Hassan Al Hail, Rola Hosni Khodair, Thahira Thekkumpurath, Abdulraheem Alrabi

    The management of status epilepticus (SE) emphasizes early identification, support of vital functions, quick implementation of pharmacotherapy, and recognition of acute etiologies. Prompt administration of a benzodiazepine, often followed by an intravenous antiseizure medication, has been supported by multiple high-quality studies. SE evolving into a refractory stage may require the initiation of anesthetic agents, such as midazolam or propofol. The contribution of autoimmune encephalitis to the burden of refractory SE cases has led to the introduction of immune-modulatory agents, such as steroids and IVIG, in the treatment protocols for refractory SE appearing de novo without prior history of epilepsy. This chapter summarizes the pharmacological agents proposed in the treatment of SE and the stepped approach to their implementation.


  • Open Access

    Neurocysticercosis in non-endemic regions: The experience of Qatar

    by Naim Haddad, Yanal Shaheen, Mohammed Abunaib, Gayane Melikyan, Ahmed El Sotouhy, Farah Wahbeh, Areej Nauman, Fatima Al-Maadid, Mohamed Soliman, Boulenouar Mesraoua, et al.

    Objective: To describe the occurrence and features of Neurocystircercosis (NCC) in Qatar.Background: Qatar has a mixed population of natives and expats. NCC is not endemic to the region, but clinical practice suggests its occurrence in large numbers.Design/ methods: A database was created to summarize information retrospectively collected on patients with NCC seen through the national health system (HMC) between 2013 and 2018. We identified demographic and disease related variables (clinical manifestations, investigative findings, treatment and outcome) for all patients.Results: Out of 420 identified NCC patients, 393 (93.6%) were men, and 98.3% were immigrants from NCC endemic countries such as Nepal (63.8%) and India (29.5%). Eighty percent of patients presented with seizures, with the majority (69%) experiencing generalized tonic–clonic seizures. Five percent presented with status epilepticus. Headaches, the second most common complaint, were reported in 18% of subjects. On imaging, 50% had a single lesion while 63% included pathology at the calcified stage. The lesions were parenchymal in 99.5% of cases, predominantly in the frontal lobe (59%). Thirteen percent were diagnosed incidentally on imaging, mainly in the form of isolated calcified non enhancing lesions. Albendazole was received by 55% of patients, and phenytoin was the most prescribed anti-seizure drug (57%). When long term follow up was available, 70% of the patients presenting with seizures were completely seizure free.Conclusion: NCC is prevalent in Qatar, mainly within the large Southeast Asian immigrant population. NCC is currently a significant contributor to the epilepsy burden in Qatar, often with a good outcome regarding seizure control. NCC with intraparenchymal single lesion shares a large proportion of our cohort.


  • Open Access

    Effect of Reperfusion Therapies on Incidence of Early Post-Stroke Seizures

    by Tasnim Mushannen, Rozaleen Aleyadeh, Maria Siddiqui, Maher Saqqur, Naveed Akhtar, Boulenouar Mesraoua, Salman Al Jerdi, Gayane Melikyan, Yanal Shaheen, Haneen Qadourah, et al.

    Objective: This study aimed to determine the effect of reperfusion therapies on the occurrence of early post-stroke seizures (PSS) in patients with acute ischemic stroke (AIS).Background: Reperfusion therapies are paramount to the treatment of stroke in the acute phase. However, their effect on the incidence of early seizures after an AIS remains unclear.Design and Methods: The stroke database at Hamad Medical Corporation was used to identify all patients who received reperfusion therapies for AIS from 2016 to 2019. They were matched with patients of similar diagnosis, gender, age, and stroke severity as measured by National Institutes of Health Stroke Scale (NIHSS) who did not receive such treatment. The rates of early PSS were calculated for each group.Results: The results showed that 508 patients received reperfusion therapies (342 had IV thrombolysis only, 70 had thrombectomies only, and 96 had received both), compared with 501 matched patients receiving standard stroke unit care. Patients who received reperfusion therapies were similar to their matched controls for mean admission NIHSS score (9.87 vs. 9.79; p = 0.831), mean age (53.3 vs. 53.2 years; p = 0.849), and gender distribution (85 vs. 86% men; p = 0.655). The group receiving reperfusion therapies was found to have increased stroke cortical involvement (62 vs. 49.3%, p < 0.001) and hemorrhagic transformation rates (33.5 vs. 18.6%, p < 0.001) compared with the control group. The rate of early PSS was significantly lower in patients who received reperfusion therapies compared with those who did not (3.1 vs. 5.8%, respectively; p = 0.042). When we excluded seizures occurring at stroke onset prior to any potential treatment implementation, the difference in early PSS rates between the two groups was no longer significant (2.6 vs. 3.9%, respectively; p = 0.251). There was no significant difference in early PSS rate based on the type of reperfusion therapy either (3.2% with thrombolysis, 2.9% with thrombectomy, and 3.1% for the combined treatment, p = 0.309).Conclusions: Treatment of AIS with either thrombectomy, thrombolysis, or both does not increase the risk of early PSS.


  • Open Access

    24-Hour video EEG in the evaluation of the first unprovoked seizure

    by Naim Haddad, Gayane Melikyan, Gonzalo Alarcon, Yanal Shaheen, Maria Siddiqi, Elfateh Ali, Boulenouar Mesraoua, Hassan AlHail, Abdulaziz Al-Abdulghani, Abdulraheem Alrabi, et al.


  • Open Access

    Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad General Hospital, Doha, Qatar

    by Boulenouar Mesraoua, Dirk Deleu, Hassan Al Hail, Musab Ali, Naim Haddad, Gayane Melykian, Yasser Osman M. Ali, Lubna El Sheikh, Ali A. Asadi-Pooya, Peter Kaplan

    This is a prospective, hospital-based study reporting an update and the prevalence of nonconvulsive status epilepticus (NCSE) in patients with altered mental status (AMS) in Qatar. Patients presenting with NCSE are compared to controls. Two-hundred and fifty patients with AMS are involved. Patients with NCSE are: 65 (12–79 years, m, 37, f, 28); controls: 185 (12–80 years, m, 101, f, 84). Occurrence of NCSE in patients with AMS was 26%. NCSE patients were younger than controls (p < 0.001). Deaths in the NCSE group occurred in 31% and 19% in controls (p < 0.0007). Hospitalization length was longer in NCSE proper and in comatose NCSE compared to controls (p < 0.02, p < 0.03). Recovery occurred in 40% of NCSE patients and 53% of controls (p < 0.08). About 31% of patients (n = 21) had refractory NCSE and 9 died. This is the first study reporting the prevalence of NCSE in Qatar. This prevalence (26%) is in the middle range. NCSE did not do better than the controls, result being disappointing regarding comatose NCSE. NCSE is an emerging condition requiring rapid diagnosis and rapid treatment. Regarding the optimal duration of continuous EGG (cEEG) monitoring to diagnose the majority of NCSE cases, 3 days of cEEG monitoring could accomplish this task.


  • Open Access

    Epilepsy in Qatar: Causes, treatment, and outcome

    by Naim Haddad, Gayane Melikyan, Hassan Al Hail, Ayman Al Jurdi, Faten Aqeel, Abdullah Elzafarany, Nour Abuhadra, Mujahed Laswi, Yasser Alsamman, Basim Uthman, et al.


  • Open Access

    Recurrent status epilepticus as the primary neurological manifestation of CADASIL: A case report

    by Naim Haddad, Catherine Ikard, Kim Hiatt, Vignesh Shanmugam, James Schmidley